浅议我国医药产业研发现状及未来发展建议

doi:10.13523/j.cb.20140718

中国生物工程杂志

2014, Vol. 34

Issue (7): 114-119 DOI: 10.13523/j.cb.20140718

专题

浅议我国医药产业研发现状及未来发展建议

濮润¹, 关镇和¹, 苏月¹, 耿向楠², 敖翼¹

1. 中国生物技术发展中心产业发展处北京 100036;
2. 中国社会科学院经济研究所北京 100836

Research & Development Status and Future Suggestions of Pharmaceutical Industry in China

PU Run¹, GUAN Zhen-he¹, SU Yue¹, GENG Xiang-nan², AO Yi¹

1. China National Center for Biotechnology Development, Beijing 100036, China;
2. Institute of Economics of the Chinese Academy of Social Sciences, Beijing 100836, China

全文: PDF(612 KB) HTML

摘要：

目前世界医药产业不断发展，逐渐形成了少数企业少数产品带来多数利润的发展新格局。我国医药产业与发达国家相比，整体处于大而不强的阶段。少数企业逐步壮大。多数药企研发投入严重不足。本文针对目前中国医药产业与研发的现状提出了自主研发“重磅炸弹”药物的方针。并从抓住创新时机、提高创新能力、走向国际竞争、培育创新环境四个方面给自主研发“重磅炸弹”药物给出建议。

关键词： 医药产业; 新药研发; “重磅炸弹”药物

Abstract:

Accomplished with the development of the worlds' pharmaceutical Industry, a new pattern that most profit is brought by few enterprises or products is established. Compare to the developed countries which have advanced pharmaceutical Industry, ours are huge but weak. Few enterprises are growing gradually while the others are short of R&D investment seriously. According to the situation of R&D and our pharmaceutical industry, we proposed a new viewpoint that helps the production of blockbuster drugs independently in this paper. And detailed recommendations on seizing the opportunity, improving innovation ability, Participating in international competition and nurturing environment for innovation were also given.

Key words: Pharmaceutical Industry New Drug Research & Development "Blockbuster" drugs

收稿日期: 2014-03-11 出版日期: 2014-07-25

ZTFLH:

通讯作者: 敖翼 E-mail: aoyi@cncbd.org.cn

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

引用本文:

濮润, 关镇和, 苏月, 耿向楠, 敖翼. 浅议我国医药产业研发现状及未来发展建议[J]. 中国生物工程杂志, 2014, 34(7): 114-119.

PU Run, GUAN Zhen-he, SU Yue, GENG Xiang-nan, AO Yi. Research & Development Status and Future Suggestions of Pharmaceutical Industry in China. China Biotechnology, 2014, 34(7): 114-119.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20140718 或 https://manu60.magtech.com.cn/biotech/CN/Y2014/V34/I7/114

[1] Garnier J.Rebuilding the R&D engine in big pharma. Harvard Business Review, 2008, 86(5): 68.

[2] 陆国庆, 吴雪钗, 胡婷婷. 恩必普.中国新药杂志, 2006, 7(15): 572-573. Lu G Q, Wu X C, Hu T T. Butylphthalide. Chinese Journal of New Drugs, 2006, 7(15): 572-573.

[3] 李国栋, 周全, 赵长文, 等. 青蒿素类药物的研究现状.中国药学杂志, 1998, 33(7): 385-389. Li G D, Zhou Q, Zhao C W, et al. Research status of artemisinin drugs. Chinese Pharmaceutical Journal, 1998, 33(7): 385-389.

[4] 姚震宇.盘点 2010年五大潜力重磅炸弹. 中国医药工业杂志, 2010, 41(12): 952-956. Yao Z W. Five potential blockbuster drugs in 2010. Chinese Journal of Pharmaceuticals, 2010, 41(12): 952-956.

[5] 付丽红, 徐建国, 尚靖. 新药研究开发中有关问题的思考. 中国药房, 2004, 15(5): 267-268. Fu L H, Xu J G, Shang J. On the problems in research and development of New Drugs. China Pharmacy, 2004, 15(5): 267-268.

[6] 樊志萍, 凌沛学. 医药技术成果转化的瓶颈与对策. 食品与药品, 2011, 13(9): 330-332. Fan Z P, Ling P X. Bottleneck and countermeasures of transformation of medical technological achievements. Food and Drug, 2011, 13(9): 330-332.

[7] DiMasi J A, Hansen R W, Grabowski H G.The price of innovation: new estimates of drug development costs.J Health Econ, 2003, 22(2): 151-186.

[8] 冯国忠, 孟令杰. 国际创新药物研究与产业化开发的特点与趋势. 生物技术产业, 2006(4): 94-97. Meng G Z, Meng L J. Features and trends on research and industrial development of international innovative drugs, Biotechnology & Business, 2006(4): 94-97.

[9] 钟敏. 未来的重磅炸弹级药物. 上海医药, 2006, 27(2): 80-83. Zhong M, Blockbuster drugs in future. Shanghai Medical & Pharmaceutical Journal, 2006, 27(2): 80-83.

[10] Trouiller P, Olliaro P, Torreele E,et al. Drug development for neglected diseases: a deficient market and a public-health policy failure.The Lancet, 2002, 359(9324): 2188-2194.

[11] 安新颖, 冷伏海. 基于结构方程模型的企业自主创新能力研究. 科技进步与对策, 2008, 25(4): 63-66. An X Y, Leng F H. Research on the Independent Innovation Capability of Enterprise Based on SEM. Science & Technology Progress and Policy, 2008, 25(4): 63-66.

[12] Bunnage M E.Getting pharmaceutical R&D back on target.Nature Chemical Biology, 2011, 7(6): 335.

[13] 李野, 游述华, 沈枫. 我国制药企业国际化经营形势分析及策略探讨. 中国药房, 2003, 14(10): 582-584. Li Y, You S H, Shen F. Study of the situation and the strategy of internationized management of Chinese pharmaceutical enterprises. China Pharmacy, 2003, 14(10): 582-584.

[14] 黎慧贞. 中美两国新药申请审评程序的差异. 中药材, 2003, 26(8): 600-602. Li H Z. Differences on new drug application review process between PRC and USA, Journal of Chinese Medicinal Materials, 2003, 26(8): 600-602.

[1]	谭清立,林岱衡,刘珈瑗,林兴纯. 基于灰色综合关联分析法的粤港澳大湾区生物医药产业效益研究^*[J]. 中国生物工程杂志, 2021, 41(6): 89-97.
[2]	尹政清,白京羽,林晓锋. 美国生物医药产业竞争力分析与启示[J]. 中国生物工程杂志, 2020, 40(9): 87-94.
[3]	黄鹏飞,陈赟,陆娇,毛开云,袁银池. *生物医药专利密集型产业发展现状及建议^——以上海市为例**[J]. 中国生物工程杂志, 2020, 40(12): 108-116.
[4]	濮润, 李萍萍, 苏月, 朱敏, 华玉涛. 我国生物医药园区发展特点及未来发展建议[J]. 中国生物工程杂志, 2015, 35(3): 104-106.
[5]	苏月刘楠. 生物医药产业发展态势与对策[J]. 中国生物工程杂志, 2009, 29(11): 123-128.
[6]	郑海涛, 林珊莉, 吴翠玲. 产业集群导向的生物医药招商引资策略[J]. 中国生物工程杂志, 2004, 24(4): 86-88.

Viewed

Full text

Abstract

Cited

Shared

Discussed